MACK - Merrimack Pharmaceuticals GAAP EPS of -$0.03 November, 03 2022 05:12 PM Merrimack Pharmaceuticals Inc. Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): Q3 GAAP EPS of -$0.03. As of September 30, 2022, Merrimack had cash and cash equivalents of $13.1 million, compared to $14.6 million as of September 30, 2021. For further details see: Merrimack Pharmaceuticals GAAP EPS of -$0.03